Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antifungal
Pharma
Scynexis secures $22M payout from GSK after trial dispute
Through the agreement, Scynexis will oblige GSK's request to cancel its phase 3 study of antifungal med Brexafemme in invasive candidiasis.
Zoey Becker
Oct 15, 2025 11:25am
GSK amends deal with Scynexis amid Brexafemme manufacturing woes
Jan 3, 2024 11:44am
GSK strikes antifungal deal as deadly pathogen raises alarm
Mar 30, 2023 11:16am
Scynexis to out license sole commercial med and cut sales team
Oct 20, 2022 3:45pm
Synexis' new data may broaden reach of game-changing Brexafemme
Apr 22, 2022 11:06am
